Stocks
Axsome Therapeutics (AXSM) EBITDA US GAAP (year values) |
|||||||||
| 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -99.1 | -123.6 | -179.8 | -174.2 | -225.0 | -300.6 | ||
| Changes by years, y/y, % | +47% | +25% | +46% | -3% | +29% | +47.1% | |||
Axsome Therapeutics. EBITDA US GAAP, bln rub
Axsome Therapeutics. EBITDA US GAAP, changes, %
Axsome Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Axsome Therapeutics (AXSM) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA, bln rub | ? | -60.4 | -96.5 | -65.4 | -78.0 | -60.6 | -300.6 | |
| Changes by years, y/y, % | +49% | +80% | +1 218% | +36% | +0% | |||
| Changes by quarters, q/q, % | +5% | +60% | -32% | +19% | -22% | |||
